HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High-dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility.

Abstract
Three newborn infants who developed hyperbilirubinemia due to blood group incompatibility were treated with high-dose gammaglobulin. Hyperbilirubinemia was caused by Rhesus (Rh) incompatibility (anti-E + anti-c) in Infant 1 and ABO incompatibility (anti-B) in Infants 2 and 3. Hyperbilirubinemia was refractory to conventional phototherapy but responded well to intravenous gammaglobulin (IVGG) at a dose of 1 g/kg in all infants. No adverse effects were observed. These findings suggest that high-dose IVGG may be useful in the treatment of hyperbilirubinemia due to isoimmune haemolytic disease resistant to phototherapy.
AuthorsK Sato, T Hara, T Kondo, H Iwao, S Honda, K Ueda
JournalActa paediatrica Scandinavica (Acta Paediatr Scand) Vol. 80 Issue 2 Pg. 163-6 (Feb 1991) ISSN: 0001-656X [Print] Sweden
PMID1709770 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Drug Combinations
  • Immunoglobulins, Intravenous
  • gamma-Globulins
  • Fibrinolysin
Topics
  • Drug Combinations
  • Erythroblastosis, Fetal (therapy)
  • Female
  • Fibrinolysin (administration & dosage)
  • Humans
  • Immunization, Passive
  • Immunoglobulins, Intravenous
  • Infant, Newborn
  • Male
  • gamma-Globulins (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: